Atinvicinib for use in treating allergic dermatitis in dogs
Concomitant administration of atinvicitinib with vaccines in dogs with allergic dermatitis ensures an effective immune response, addressing the immunosuppression issue and maintaining protection against diseases without treatment withdrawal.
Patent Information
- Application Number
- PCT/EP2026/062854
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
Existing treatments for allergic dermatitis in dogs, such as Janus kinase (JAK) inhibitors, compromise the immune response when administered concurrently with vaccines, leading to increased risks of immunosuppression and inadequate protection against diseases.
A veterinary pharmaceutical composition comprising atinvicitinib is administered concomitantly with vaccines, ensuring an effective immune response without the need to withdraw treatment before or after vaccination.
The composition allows for uninterrupted treatment of allergic dermatitis while ensuring the dog develops an adequate immune response to vaccines, reducing the risk of immunosuppression and providing effective protection against common canine diseases.
Smart Images

Figure IMGF000003_0001
Abstract
Description
[0001] Method of using atinvicitinib
[0002] TECHNICAL FIELD
[0003] The present invention relates to the use of a veterinary pharmaceutical composition comprising atinvicitinib
[0004] BACKGROUND
[0005] Atopic dermatitis and allergic dermatitis are common skin conditions in dogs that can significantly affect their quality of life. Traditional treatments sometimes require the withdrawal of medications prior to vaccination, which can compromise the animal's immune response. The present invention addresses this issue by providing a composition that allows for the concomitant administration of atinvicitinib and vaccines, ensuring an adequate immune response while treating dermatitis.
[0006] Vaccination of dogs is a standard practice widely adopted by pet owners and veterinarians to safeguard against several serious and potentially life-threatening diseases. The core vaccination program typically includes vaccinations for distemper, parvovirus, adenovirus (hepatitis), and rabies, but depending on region can include canine parainfluenza and leptospira, and bordetella.
[0007] Adequate response to vaccination requires a response from the animal’s immune system. Animals that are immune compromised as a result of illness or medication might not be able to generate an appropriate immune response to vaccination, thus the vaccine may fail to induce protection.
[0008] When modified live vaccines are used, there might also be the capacity for the vaccine to cause disease in an immunocompromised patient.
[0009] Several vaccines for prevention of diseases associated with various viral and bacterial diseases in dogs are available that protect dogs from the most common diseases. Examples are vaccines that aid in preventing canine distemper (CD) caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza (CPI) caused by canine parainfluenza (CPI) virus, and canine parvoviral enteritis caused by canine parvovirus (CPV), caninerabies caused by rabies virus (RV), many of these are in the core vaccination program for dogs that are usually repeated yearly.
[0010] Canine distemper (CD) is a high morbidity, high mortality viral disease occurring in unvaccinated dog populations worldwide. Approximately 50% of non-vaccinated, non-immune dogs infected with canine distemper (CD) virus (CDV) develop clinical signs and approximately 90% of those dogs die. ICH, caused by CAV-1 , is a universal, sometimes fatal, viral disease of dogs characterized by hepatic and generalized endothelial lesions. The respiratory disease caused by CAV-2, in severe cases, may include pneumonia and bronchopneumonia. CAV-2 vaccine has been shown to cross-protect against ICH caused by CAV-1. The upper respiratory disease caused by CPI virus may be mild or subclinical, with signs becoming more severe if concurrent infection with other respiratory pathogens exists. The enteric disease caused by CPV is characterized by sudden onset of vomiting and diarrhea, often hemorrhagic, and may be accompanied by leukopenia. CPV is often lethal in puppies.
[0011] Major animal health companies market core canine vaccines in their companion animal vaccine franchise.
[0012] The four types of canine allergic dermatitis — atopic dermatitis, flea allergy dermatitis, food-responsive dermatitis and other — are categorized according to their triggers and underlying causative factors. The patterns of clinical signs can overlap between the different types, sometimes requiring complex diagnostic procedures. Regardless of the type of allergic dermatitis, the most prominent presenting sign is pruritus which has a negative impact on the quality of life of dogs and owners alike.
[0013] Atopic dermatitis is a common allergic skin condition in dogs, affecting approximately 10-15% of the canine population. It is characterized by symptoms such as intense itching, redness, and inflammation of the skin, often leading to secondary infections. Affected dogs may also experience hair loss and chronic ear infections, significantly impacting their quality of life.
[0014] Janus kinase (JAK) inhibitors, such as oclacitinib (Apoquel® by Zoetis) and ilunocitinib (Zenrelia® by Elanco), are effective treatments for allergic dermatitis indogs. These medications work by targeting specific pathways in the immune response, significantly reducing itching and inflammation.
[0015] Another JAK inhibitor is atinvicitinib, CAS # 2169273-59-8.
[0016] WO 2018 / 108969 discloses compounds of formula I which are selective Janus kinase (JAK) inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as allergic dermatitis including atopic dermatitis, arthritis, and cancer.
[0017] Specifically, atinvicitinib, 1 -[(3R,4S)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl)amino]pyrazole-4-carboxamide (I) is disclosed.
[0018] I2I
[0019] 'N,
[0020]
[0021] Formula (I)
[0022] WO 2020 / 120673 and WO 2020 / 221914 disclose processes to make atinvicitinib. WO 2021 / 123108 discloses pharmaceutical compositions comprising atinvicitinib.
[0023] WO2023 / 118555 discloses methods of treating allergic dermatitis including atopic dermatitis in young dogs with atinvicitinib.
[0024] Studies to investigate the serological immune response under treatment with JAK inhibitors (Vaccine response studies) have been conducted for JAK inhibitors like oclacitinib and ilunocitinib during their development. The results of these studies indicate an increased risk of immunosuppression in animals treated with these JAK inhibitors, leading to an increased risk of secondary infections or a less effective protection against canine diseases.
[0025] When administered overdose treatment of oclacitinib in a vaccine response study, the dogs were able to develop protective titers but showed severe clinical signs related to immunosuppression (pneumonia, sepsis), which finally led to unscheduled euthanasia of two study dogs. See Apoquel NADA 141-345 FOI pp 25-27 Vaccine Response Study.In a similar vaccine response study with overdose treatment with ilunocitinib, two dogs showed severe clinical signs that ultimately resulted in unscheduled euthanasia. One of these dogs was diagnosed with adenoviral hepatitis due to Zenrelia® induced immunosuppression. Amongst other clinical findings, seven of eight Zenrelia® treated study dogs showed clinical signs associated with Cystoisospora canis infection secondary to Zenrelia®-induced immunosuppression. While the six remaining Zenrelia®-treated dogs were able to demonstrate an adequate immune response against CAV-2 and CPV, four of the six dogs failed to demonstrate an adequate immune response to Rabies virus and one of the six dogs failed to demonstrate and adequate immune response to canine distemper (CD) virus. These findings resulted in a boxed warning on the US Zenrelia® label to withdraw treatment with Zenrelia® prior and post vaccination. See Zenrelia NADA 141-585 FOI pp 26-29 Vaccine Response Study.
[0026] It has been found that treated animals are at risk of fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine. Therefore, it is not recommended to administer vaccines to a dog receiving such treatment.
[0027] As allergic conditions can require lifelong treatment and some cases show quick relapses (within days) when withdrawing the treatment, there is a need for methods of administering JAK inhibitors concurrently with vaccines that avoid such drawbacks.
[0028] SUMMARY OF INVENTION
[0029] A veterinary pharmaceutical composition comprising an effective dose of atinvicitinib and a pharmaceutically acceptable carrier for use in the treatment of a dog against allergic dermatitis including atopic dermatitis without the need to withdraw treatment prior or post vaccination, characterized in that the composition is administered concomitantly with vaccination and results in adequate immune response to vaccination.DETAILED DESCRIPTION
[0030] It is to be understood that the invention is not limited to exemplified methods or compositions disclosed herein. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only and is not intended to be limiting.
[0031] Before describing the present invention in detail, some terms used in the context of the present invention will be defined. In addition to these terms, others are defined elsewhere in the specification, as necessary.
[0032] Unless otherwise expressly defined herein, terms of art used in this specification will have their art-recognized meanings.
[0033] As used in the specification and claims, the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise.
[0034] As used herein, the term “comprising” is intended to mean that the compositions and methods include the recited elements but not excluding others.
[0035] Provided herein is a treatment regimen for dogs that enables vaccination of dogs that are currently treated with a pharmaceutical composition according to the invention with atinvicitinib as active ingredient or scheduled to start atinvicitinib treatment within the next 28 days and require the administration of a vaccine. The current inventors found that when using a pharmaceutical composition according to the invention there is no need to withdraw atinvicitinib treatment prior or post vaccination or to postpone vaccination in view of the atinvicitinib treatment.
[0036] The ability to administer atinvicitinib concomitantly with vaccination according to the current invention without compromising the immune response to the vaccination is a significant advancement. It allows for the uninterrupted treatment of allergic dermatitis including atopic dermatitis while ensuring that the dog develops adequate serological immune response within the expected timeframe.
[0037] Continuous treatment helps maintain control over symptoms such as itching, redness, and inflammation and ensures that the dog experiences less discomfort and better overall well-being when the symptoms are managed effectively. At the sametime the effective protection by an adequate immune response by the vaccine administration is achieved.
[0038] Concomitant generally means occurring during the same time period. In this application the “administration of the composition concomitantly with vaccination” means that the animal can be vaccinated at any time during the atinvicitinib treatment, including on the same day. This means that there is no need to withdraw treatment prior or post vaccination.
[0039] "Vaccine” and “vaccination” refers to (the administration of) a composition that includes an antigen, as defined herein. Administration of the vaccine to an animal results in an immune response, generally against one or more specific diseases. The amount of a vaccine that is effective may vary depending on the particular virus used, or the condition of the dog, and can be determined by a veterinary physician. The vaccine may be introduced directly into the subject by the subcutaneous, oral, oronasal, or intranasal routes of administration.
[0040] An adequate immune response after vaccination refers to the animal body's ability to recognize and effectively respond to a pathogen (such as a virus or bacterium) following immunization. It is sometimes called protective immunity.
[0041] The immune response of an animal to a vaccine may be evaluated, e.g., indirectly through measurement of antibody titers, lymphocyte proliferation assays, or directly through monitoring signs and symptoms after challenge with wild type strain.
[0042] An adequate immune response to a vaccination in general leads to a protection of the vaccinated animal against infection or disease.
[0043] ” Protection” or “protecting against infection or disease" means having an improvement of the disease in a vaccinated target animal when compared to a nonvaccinated animal. For example, by reducing the number or the duration of the viral and / or bacterial replication in an animal, or reducing the intensity, or the severity of the infection. Also, or consequentially, the vaccination provides protection when there is a reduction or amelioration of the (clinical) signs of disease that may be caused by such infection. As used herein, the terms “protecting", or “providing protection to", do not require complete protection from any indication of infection.For example, "for use in the protection" can mean that the provided protection is sufficient such that, after challenge, symptoms of the underlying infection are at least reduced, and / or that one or more of the underlying cellular, physiological, or biochemical causes or mechanisms causing the symptoms are reduced and / or eliminated. It is understood that “reduced,” as used in this context, means relative to the state of the infection, including the molecular state of the infection, not just the physiological state of the infection. Hence, the term “protection" encompasses a prophylactic treatment against infection with the virus bacterium or against a disorder arising from the infection.
[0044] The level of protection achieved by vaccination with a vaccine is typically higher than 10%, preferably higher than 20% or may be higher than 30%, 40%, 50%, 60%, 70%, 80% and is more preferably 90% or higher. For example, this means that a level of protection of 50% means that there is a 50% reduction or amelioration of the (clinical) symptoms of disease when compared to infected but not vaccinated animals. This means for example 50% less viral replication, and / or that the clinical signs have reduced by 50%.
[0045] When the immune response of an animal to a vaccine is evaluated, serological tests are commonly used to measure antibody levels (e.g., ELISA tests). The skilled person is aware of the methodology of such testing.
[0046] The serological immune response refers specifically to the production of antibodies in the serum in response to an antigen. This response is generally considered for most dog vaccines a key indicator of the effectiveness of vaccination.
[0047] The adequacy of the (serological) immune response can be evaluated through various tests that measure specific antibody levels against the pathogens included in the vaccine.
[0048] Common indicators include Virus Neutralization Tests (VNT): These tests measure the ability of antibodies to neutralize viruses, such as CDV and CAV-2. A higher neutralization titer indicates a stronger immune response. Hemagglutination Inhibition Tests (HAI): These tests assess the immune response to viruses like CPV by measuring the ability of antibodies to prevent the agglutination of red blood cells. Enzyme-Linked Immunosorbent Assay (ELISA): This test can quantify specificantibodies in the serum, providing a direct measure of the immune response to vaccination.
[0049] For Canine Distemper Virus (CDV), Canine Adenovirus (CAV) and Canine Parvovirus (CPV) s and for rabies virus (RV), the presence of antibodies is widely held to indicate protection in an animal that has mounted its own active immune response. Antibodies are not the sole mediator of protection, but their presence in the serum of an animal over 20 weeks of age is held to indicate protection against the CDV, CAV and CPV viruses and for rabies virus.
[0050] The measurement of an adequate immune response after vaccination typically occurs at specific time points, which can vary depending on the type of vaccine and the disease it targets. The peak response usually occurs between 4 to 8 weeks after vaccination. This timeframe is commonly used to measure the peak levels of antibodies and assess the adequacy of the immune response. Some vaccines show their highest antibody levels during this period.
[0051] In one embodiment the adequate immune response to the concomitantly administered vaccine is tested at 8 weeks after vaccination.
[0052] Several vaccines for prevention of diseases associated with various viral and bacterial diseases in dogs are available that protect dogs from the most common diseases.
[0053] Such vaccines act as an aid in preventing canine distemper (CD) caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza (CPI) caused by canine parainfluenza (CPI) virus, and canine parvoviral enteritis caused by canine parvovirus (CPV), canine rabies caused by rabies virus (RV)
[0054] In one embodiment the concomitantly administered vaccine comprises antigens that protect dogs against canine distemper caused by canine distemper virus; infectious canine hepatitis caused by canine adenovirus type 1 ; respiratory disease caused by canine adenovirus type 2 or canine respiratory coronavirus; canine parainfluenza caused by canine parainfluenza virus; enteritis caused by canine coronavirus orcanine parvovirus; leptospirosis caused by Leptospira canico\a, L grippotyphosa, L icterohaemorrhagiae, L pomona, or L Bratislava', and infectious tracheobronchitis ("kennel cough") caused by Bordetella bronchiseptica.
[0055] Several dog vaccines include these antigens either as single antigen or in various combinations. Because of the complexity of many disease syndromes and to avoid giving animals multiple injections, it is common to use mixtures of antigens in single vaccines.
[0056] In one embodiment, the vaccine comprises one or more live viruses, one or more modified-live viruses, one or more inactivated viruses, or combinations thereof.
[0057] Other types of vaccines are suitable for the current invention as well. Such alternatives are known to the skilled person and include subunit vaccines recombinant vaccines such as e.g., DNA vaccines, RNA vaccines, VLP vaccines, and vector vaccines etc.
[0058] In another preferred embodiment the concomitantly administered vaccine comprises a modified live Canine Adenovirus type-2 (CAV-2), a modified live Canine Distemper Virus (CDV), a modified live Canine Parvovirus (CPV), and / or inactivated Rabies Virus (RV). Other antigens might be present in addition to these antigens.
[0059] By including modified live vaccines for CAV-2, CDV, and CPV, along with an inactivated rabies vaccine, the composition provides broad protection against some of the most serious infectious diseases affecting dogs.
[0060] The immune response of the vaccinated animal can be measured through serological testing as discussed earlier, providing a quantitative assessment of the immune response. This measurement uses standard methods and can be either performed in specialized laboratories or alternatively using commercial test kits. The skilled person is aware of the situations in which such test kits can be used.
[0061] Specific thresholds for antibody levels indicate whether a dog has developed adequate immunity against particular pathogens.
[0062] It has been found that the immune response of the vaccinated animal with concomitant administration of the atinvicitinib composition is non-inferior over the immune response compared to a mono-administration of the vaccine compositionwithout concomitant administration of the atinvicitinib composition. Non- inferior means that the product works in general about as well as the comparator. The skilled person can determine the appropriate non-inferiority margin depending on the specific antigen.
[0063] These thresholds are based on established correlations between antibody levels and protection against disease, derived from clinical studies and veterinary guidelines. See World Small Animal Veterinary Association (WSAVA) Vaccination Guidelines, Journal of Small Animal Practice, 2024.
[0064] Quantification of vaccinal antibody titers relies on viral neutralization (VN) for CDV and CAV and hemagglutination inhibition (HI) for CPV as reference standards.
[0065] In one embodiment with respect to CDV, CPV, CAV-2 and RV meets the following specific criteria for adequate serological immune response.
[0066] Canine Distemper Virus (CDV):VN50 Level: The VN50 (Virus Neutralization 50) level is a measure of the serum's ability to neutralize the virus. A VN50 level of at least > 32 indicates that the dog has a sufficient antibody response to provide protection against CDV.
[0067] Canine Parvovirus (CPV): HAI Level: The HAI (Hemagglutination Inhibition) test measures the ability of antibodies to prevent the agglutination of red blood cells by the virus. An HAI level of > 80 indicates a strong immune response to CPV.
[0068] Canine Adenovirus Type 2 (CAV-2): VN50 Level: For CAV-2, an adequate immune response is indicated by a VN50 level of > 16. This level reflects the serum's ability to neutralize the virus effectively.
[0069] Rabies Virus (RV): lU / mL Level: For rabies, an adequate immune response is indicated by an antibody level of > 0.5 lU / mL. This measurement is based on the International Units (IU) standard for rabies antibody levels.
[0070] In one embodiment the vaccine includes live, attenuated strains of pathogens. Live, attenuated vaccines are formulated using live pathogens that have been weakened (attenuated) so that they cannot cause disease in healthy individuals. These vaccines stimulate a robust immune response without causing the actual disease. Theattenuation process typically involves modifying the pathogen through genetic manipulation, heat treatment, or chemical treatment to reduce its virulence while preserving its ability to provoke an immune response. The level of attenuation is critical to vaccine success. Under attenuation will result in residual virulence and disease (reversion to virulence); over attenuation will result in an ineffective vaccine.
[0071] Live, attenuated vaccines are widely used in veterinary medicine to protect dogs against several infectious diseases, including Canine Distemper Virus (CDV), Canine Parvovirus (CPV), Canine Adenovirus Type 2 (CAV-2), and Canine Parainfluenza Virus.
[0072] While live, attenuated vaccines are generally considered safe, there are considerations regarding their use in immunocompromised animals.
[0073] When modified live vaccines are used, there is a risk that the vaccine cause disease in an immunocompromised animal.
[0074] Commercial vaccines such as for example, Nobivac EDGE® Lepton Nobivac EDGE® DAPPv, Nobivac EDGE® DAPPv+L4, Nobivac EDGE® Lepto4, Nobivac® NXT Canine Flu H3N2, Nobivac® INTRA-TRAC® ORAL BbPi, NOBIVAC® INTRATRAC® ORAL Bb, NOBIVAC® INTRA-TRAC® ORAL ADT, NOBIVAC® INTRA-TRAC® KC, NOBIVAC® INTRA-TRAC®, NOBIVAC® LEPTO4, NOBIVAC® LYME , NOBIVAC® DHPPi, NOBIVAC® DHP, NOBIVAC® Parvo C, NOBIVAC® L4, NOBIVAC® LEPTO, Nobivac® Respira Bb, Nobivac® KC, Nobivac® Pi, Nobivac® Puppy DP, Nobivac® Puppy DPv, Nobivac® DP PLUS, Nobivac® Rabies, Nobivac® RL, Nobivac® NXT Rabies, Nobivac® Canine Flu H3N2, Nobivac® Canine Flu H3N8, Nobivac® Canine Flu bivalent, Nobivac® Lepto4, Nobivac® 1 Canine DAPPv, and Nobivac® Canine 1 DAPPv+L4, are vaccines contemplated for use with this invention.
[0075] Surprisingly it has been found that no adverse clinical effects have been observed when atinvicitinib has been used concomitantly with vaccines that included live, attenuated antigens.Veterinary Pharmaceutical Compositions
[0076] The term “composition”, as in pharmaceutical composition, is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) (pharmaceutically acceptable excipients) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
[0077] Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing atinvicitinib, and at least one pharmaceutically acceptable excipient.
[0078] In various embodiments, atinvicitinib is formulated in unit dose form as a tablet or capsule. In some embodiments, the tablet or capsule is chewable.
[0079] In one embodiment the pharmaceutical composition for use in the current invention is a unit dose for oral administration, preferably a tablet comprising a flavoring that is palatable to an intended companion animal.
[0080] In various embodiments, atinvicitinib is formulated in a composition that comprises a flavoring palatable to an intended animal. For example, in some instances a formulation is provided comprising a flavoring palatable to a canine. Suitable flavorings include beef, chicken, pork, fish, and turkey flavorings, or any other flavoring used for canine foods. In one embodiment, the flavoring is a preparation comprising one or more of beef liver, chicken liver, pork liver, and turkey liver.
[0081] In one embodiment, the present invention provides an orally administered, chewable, flavored pharmaceutical composition of atinvicitinib for the treatment of atopic or allergic dermatitis in dogs. Preferably such animals are younger than 12 months of age at initiation of the treatment.
[0082] Such pharmaceutical compositions can be in general prepared using standard formulation processes and equipment and can comprise in addition to a compound of Formula (I) an additional active ingredient, e.g., as described earlier.Another aspect of the present invention provides pharmaceutical compositions for use in the current invention comprising atinvicitinib with a pharmaceutically acceptable carrier. Physiologically acceptable formulation carriers and excipients are known in the art and are described for example in “Gennaro, Remington: The Science and Practice of Pharmacy” (20thEdition, 2000). All such ingredients, carriers and excipients must be substantially pharmaceutically or veterinary pure and nontoxic in the amounts employed and must be compatible with the pharmaceutically active ingredients (i.e. atinvicitinib).
[0083] For the treatment of any of the diseases, atinvicitinib may be administered orally, by inhalation spray, topically, parenterally or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
[0084] The veterinary pharmaceutical compositions containing atinvicitinib as the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
[0085] Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
[0086] Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, com starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.
[0087] The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water-miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
[0088] Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions.
[0089] Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate.
[0090] The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
[0091] Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
[0092] Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
[0093] Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
[0094] The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsion.
[0095] The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
[0096] Suitable emulsifying agents may be naturally occurring phosphatides, for example soybean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
[0097] The emulsions may also contain sweetening and flavoring agents.
[0098] Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose.
[0099] Such formulations may also contain a demulcent, a preservative, and flavoring and coloring agents.
[0100] The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension.
[0101] This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
[0102] The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butane diol.Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
[0103] Cosolvents such as ethanol, propylene glycol or polyethylene glycols may also be used.
[0104] In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.
[0105] For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides.
[0106] In addition, fatty acids such as oleic acid find use in the preparation of injectables.
[0107] Dose Ranges
[0108] A “therapeutically effective dose” or “therapeutically effective amount” refers to an amount of a compound or composition of this invention that is sufficient to produce a desired effect, which can be a therapeutic and / or beneficial effect. It is an amount that is non-toxic to the animal, and sufficient to achieve the desired effect, by reducing the signs and symptoms associated with a disease or disorder.
[0109] For allergic diseases such effect is e.g., a reduction or elimination in the severity and / or frequency of symptoms and / or improvement or remediation of damage (e.g., a reduction, delay, and / or prevention of flares) and / or reducing, inhibiting, relieving or preventing lesions and / or itch in an animal with atopic or allergic dermatitis.
[0110] Non-toxic in this document means that at the specific dosage there are no severe side reactions in the treated animal. This means specifically, if side effects are observed they are acceptable, e.g., clinical or microscopic findings are temporary and resolve without requiring (long) treatment or other intervention or show only a small magnitude of change (such as for hematology parameters).
[0111] Another important aspect for such a chronic disease is that the treatment with the therapeutically effective and non-toxic dosage of atinvicitinib that controls pruritus results in a significant improvement of the quality of life of the animal (and the pet owner). This is also important from an animal welfare standpoint because such a chronic disease results in continuous discomfort of the animal. Especially for youngdogs between the age of approximately 6 months and 12 months continuous itching disturbs mental and physical development, can result in undesired behavior of the animal and can negatively impact socialization of the young (dog) animal.
[0112] The therapeutically effective daily dosage of the atinvicitinib is from about 0.1 mg / kg to about 6.0 mg / kg. In one embodiment, the therapeutically effective dose is from about 0.25 mg / kg to about 3.0 mg / kg per day, preferably 0.5 to about 1.8 mg / kg body weight per day or about 0.6 mg / kg to about 1.2 mg / kg body weight or alternatively 1 mg / kg bodyweight.
[0113] Preferably a therapeutically effective dose of the atinvicitinib is administered orally to the animal. This has the advantage that the administration does not require the intervention of a veterinarian and can be continued over a long period of time.
[0114] Some allergic conditions require a lifelong treatment. In many embodiments, treatment will continue on a consecutive daily basis (as a maintenance therapy) for many weeks, if not for the rest of the animal's life.
[0115] Typically, treatment is continued with daily administration repeated for at least 7 consecutive days, if not longer, i.e. , for at least a month, preferably at least six months. In many embodiments, daily treatment is continued for at least a year, if not longer, i.e., 5 years to the rest of the animal's life.
[0116] In one embodiment the administration is repeated daily for at least six months.
[0117] In another embodiment the administration is repeated daily for at least a year.
[0118] The desired therapeutically effective dose may conveniently be presented in a single daily dose, or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day
[0119] Also, it is to be understood that the initial dosage administered may be increased beyond the above upper level in order to rapidly achieve the desired plasma concentration. On the other hand, the initial dosage may be smaller than the optimum and the daily dosage may be progressively increased during the course of treatment depending on the particular situation.The daily dose may also be divided into multiple doses for administration, e.g., two times per day e.g., the daily dose is split into % of the daily dose that is administered twice per day approximately 12 hours apart.
[0120] In one embodiment a dose of the atinvicitinib is administered initially twice daily for two to six weeks and the same dose as maintenance therapy once daily thereafter. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the particular mode of administration. For example, a formulation intended for the oral administration may contain from 0.05 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 99.95 percent of the total composition. Dosage unit forms will generally contain between from about 0.1 mg to about 0.4 g of an active ingredient, typically 0.5 mg, 1 mg, 2 mg, 3 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, or 400 mg.
[0121] The concentration of the active ingredient or drug load in the dosage form may be about 0.1 % to about 10% or about 1 % to 5 % or about 3%.
[0122] The magnitude of therapeutic dose of atinvicitinib will on the indication and the seventy of the condition to be treated as will its route of administration. In general, the daily dose from about 0.01 mg to about 10 mg per kg body weight of a dog, preferably 0.1 mg to about 6 mg per kg. In another embodiment, the daily dose is from about 0.2 mg per kg to about 1.5 mg / kg of body weight of a dog. In another embodiment, the daily dose is from about 0.1 mg per kg to about 3.0 mg / kg of body weight of a dog. On the other hand, it may be necessary to use dosages outside these limits in some cases.
[0123] In another embodiment, the composition for use is characterized in that the effective dose of atinvicitinib is between about 0.1 to about 6 mg / kg.
[0124] In another embodiment, the composition for use is characterized in that the atinvicitinib is administered once daily at a daily dose of 0.5-3.6 mg / kg body weight (BW).In another embodiment, the composition for use is characterized in that the daily dose is 0.8-1.2 mg / kg bodyweight of the animal.
[0125] In another embodiment, the composition for use is characterized in that a blood level of atinvicitinib in the dog at the time of vaccination is at least 100 ng / mL.
[0126] In another embodiment, the composition for use is characterized in that the composition is administered concomitantly with vaccination at the same time or within 28 days of each other, and wherein the immune response to the vaccine composition is non-inferior compared to a mono-administration of the vaccine composition without concomitant administration of the atinvicitinib composition.
[0127] In another embodiment, the composition for use is characterized in that the treated dog is vaccine naive. Vaccine naive means that the animal did not receive a vaccination yet.
[0128] In another embodiment, the composition for use is characterized in that the dog is younger than 12 months.
[0129] In one embodiment the age of the treated animal is between approximately 6 and 12 months of age.
[0130] Signs of allergic dermatitis including atopic dermatitis develop already in young adult animals below the age of 12 months. The age of onset of canine allergic dermatitis is typically between 6 months and 3 years. Affected dogs of this age show pruritus or other clinical manifestations associated with allergic dermatitis including atopic dermatitis.
[0131] Therefore, animals younger than 12 months, especially with dermatological symptoms (such as pruritus) can be (already) treated at the onset of such symptoms at a young age.
[0132] On the other hand, at this age the basic vaccination of the young animal is due or not yet completed. It is very important that the animals can be vaccinated at this age and develop an adequate immune response because otherwise they are unprotected against infections and serious, potentially fatal diseases after diminishing of the maternal antibodies.Adequate blood levels of atinvicitinib in the animal are necessary to ensure that the drug can effectively inhibit the JAK pathways involved in the inflammatory response associated with allergic dermatitis including atopic dermatitis. Achieving a blood level of at least 50 ng / ml, or 100 ng / mL is associated with effective inhibition of the JAK pathways, which is necessary for managing inflammation and pruritus in dogs with dermatitis.
[0133] It should be noted that, as used in this specification and the appended claims, singular articles such as "a," "an," and "the," may refer to one object or to a plurality of objects unless the context clearly indicates otherwise. Thus, for example, reference to a composition containing "a compound" may include a single compound or two or more compounds.
[0134] DESCRIPTION OF EMBODIMENTS
[0135] An embodiment of the invention is veterinary pharmaceutical composition comprising an effective dose of atinvicitinib and a pharmaceutically acceptable carrier for use in the treatment of a dog against atopic dermatitis or allergic dermatitis without the need to withdraw treatment prior or post vaccination, characterized in that the composition is administered concomitantly with vaccination and results in adequate immune response to vaccination.
[0136] In another embodiment, the composition for use is characterized in that the adequate immune response is at 8 weeks after vaccination.
[0137] In another embodiment, the composition for use is characterized in that the vaccine includes live, attenuated strains of pathogens.
[0138] In another embodiment, the composition for use is characterized in that the vaccine includes a killed vaccine.
[0139] In another embodiment, the composition for use is characterized in that the concomitantly administered vaccine comprises antigens that protects dogs against canine distemper caused by canine distemper virus; ) infectious canine hepatitis caused by canine adenovirus type 1 ; respiratory disease caused by canine adenovirus type 2 or canine respiratory coronavirus; canine parainfluenza caused bycanine parainfluenza virus; enteritis caused by canine coronavirus or canine parvovirus; leptospirosis caused by Leptospira canicola, L grippotyphosa, L icterohaemorrhagiae, L pomona, or L Bratislava', and infectious tracheobronchitis ("kennel cough") caused by Bordetella bronchiseptica.
[0140] In another embodiment, the composition for use is characterized in that the vaccine comprises antigens that protects dogs against a disease caused by a pathogen selected from the group consisting of canine distemper virus (CDV), canine adenovirus type 2 (CAV-2), canine parvovirus (CPV)) or and rabies virus (RV).
[0141] In another embodiment, the composition for use is characterized in that the concomitantly administered vaccine comprised modified live Canine Adenovirus type-2 (CAV), modified live Canine Distemper Virus (CDV), modified live Canine Parvovirus (CPV), and inactivated Rabies Virus (RV.
[0142] In another embodiment, the composition for use is characterized in that the adequate immune response is an adequate serological immune response.
[0143] In another embodiment, the composition for use is characterized in that the adequate serological immune response is one or more of
[0144] i) CDV having (VN50 level of at least > 32)
[0145] ii) CPV (HAI > 80)
[0146] iii) CAV-2 (VN50 > 16) or
[0147] iv) RV (> 0.5 lU / mL).
[0148] The measurement of an adequate immune response after vaccination typically occurs at specific time points, which can vary depending on the type of vaccine and the disease it targets.
[0149] The peak response usually occurs between 4 to 8 weeks after vaccination. This timeframe is commonly used to measure the peak levels of antibodies and assess the adequacy of the immune response. Some vaccines show their highest antibody levels during this period.In one embodiment the adequate immune response to the concomitantly administered vaccine is tested at 8 weeks after vaccination.
[0150] In another embodiment, the one or more of the antibodies titers are measured at about 20 days, 30 days, 45 days, 56, days, 60 days, 68 days, 75 days, 90 days, 120 days, 150 days, 168 days, 180 days, 8 weeks, 12 weeks, 16 weeks or 24 weeks. In another embodiment, the composition for use is characterized in that the effective dose of atinvicitinib is between about 0.1 to about 6 mg / kg
[0151] In another embodiment, the composition for use is characterized in that the atinvicitinib is administered once daily at a daily dose of 0.5-3.6 mg / kg BW.
[0152] In another embodiment, the composition for use is characterized in that the daily dose is 0.8-1.2 mg / kg bodyweight of the animal.
[0153] In another embodiment, the composition for use is characterized in that the composition is administered concomitantly with vaccination at the same time or within 28 days of each other, and wherein the immune response to the vaccine composition is non-inferior compared to a mono-administration of the vaccine composition_without concomitant administration of the atinvicitinib composition.
[0154] In another embodiment, the composition for use is characterized in that the treated dog is vaccine naive.
[0155] In another embodiment, the composition for use is characterized in that the dog is younger than 12 months.
[0156] In another embodiment, the composition for use is characterized in that the dog is at least 6 months old.
[0157] An embodiment of the invention is a method of vaccinating a dog that is concurrently treated with atinvicitinib comprising
[0158] a) administering to the dog a veterinary pharmaceutical composition comprising an effective dose of atinvicitinib and a pharmaceutically acceptable carrier where in the effective dose is between about 0.1 to about 6 mg / kg andb) administering one or more vaccines,
[0159] wherein one or more antibodies titers of the one or more vaccines are maintained at an adequate serological immune response.
[0160] In an embodiment, the one or more antibodies titers of the one or more vaccines are are measured to show an adequate serological immune response at day 20.
[0161] In another embodiment, the administration of the atinvicitinib is twice a day, daily, weekly, bimonthly or monthly.
[0162] In another embodiment, the administration of the atinvicitinib is oral.
[0163] In another embodiment, the one or more vaccines protect the dog against canine distemper caused by canine distemper virus(CDV); infectious canine hepatitis caused by canine adenovirus type 1 ; respiratory disease caused by canine adenovirus type 2 (CAV-2) or canine respiratory coronavirus; canine parainfluenza caused by canine parainfluenza virus; enteritis caused by canine coronavirus or canine parvovirus (CPV); leptospirosis caused by Leptospira canicola, L grippotyphosa, L icterohaemorrhagiae, L pomona, or L Bratislava', and infectious tracheobronchitis ("kennel cough") caused by Bordetella bronchiseptica or rabies virus (RV).
[0164] In another embodiment, the vaccine is one that protects the dog against canine distemper virus (CDV).
[0165] In another embodiment, the vaccine is one that protects the dog against canine adenovirus type 2 (CAV-2).
[0166] In another embodiment, the vaccine is one that protects the dog against canine parvovirus (CPV).
[0167] In another embodiment, the vaccine is one that protects the dog against rabies virus (RV).
[0168] In another embodiment, the effective dose atinvicitinib is between about 0.1 to about 5.0 mg / kg, between about 1.0 to about 4.0 mg / kg, between about 1.0 to about 2.0 mg / kg, or between about 2.0 to about 3.0 mg / kg.In another embodiment, the one or more of the antibodies titers are measured at the following levels:
[0169] i) CDV (VN50 > 32)
[0170] ii) CPV (HAI > 80)
[0171] iii) CAV-2 (VN50 > 16) or
[0172] iv) RV > 0.5 lU / mL).
[0173] In another embodiment, the one or more of the antibodies titers are measured at about 20 days, 30 days, 45 days, 56, days, 60 days, 68 days, 75 days, 90 days, 120 days, 150 days, 168 days, 180 days, 8 weeks, 12 weeks, 16 weeks or 24 weeks. In one embodiment the adequate immune response to the concomitantly administered vaccine is measured at 8 weeks, or at 12 weeks after vaccination. An embodiment of the invention is a method of vaccinating a dog that has been treated with atinvicitinib comprising
[0174] a) administering daily to the dog a veterinary pharmaceutical composition comprising an effective dose of atinvicitinib and a pharmaceutically acceptable carrier where in the effective dose is between about 0.1 to about 6 mg / kg and
[0175] b) administering one or more vaccines.
[0176] In an embodiment, the vaccines protect the animal against a disease caused by one or more of canine distemper virus (CDV), canine adenovirus type 2 (CAV-2), canine parvovirus (CPV)) or rabies virus (RV).
[0177] An embodiment of the invention is a method of treating a dog for atopic dermatitis and protecting the dog against an infectious disease comprising administering to the dog a veterinary pharmaceutical composition comprising an effective dose of atinvicitinib and a pharmaceutically acceptable carrier and administering one or more vaccines wherein the effective dose of the atinvicitinib is between about 0.1 to about 6 mg / kgs and the administering of the one or more vaccines occurs before, simultaneous to or after receiving the veterinary pharmaceutical composition.In an embodiment, the infectious disease is one or more of canine distemper caused by canine distemper virus(CDV); infectious canine hepatitis caused by canine adenovirus type 1 ; respiratory disease caused by canine adenovirus type 2 (CAV-2) or canine respiratory coronavirus; canine parainfluenza caused by canine parainfluenza virus; enteritis caused by canine coronavirus or canine parvovirus (CPV); leptospirosis caused by Leptospira canicola, L grippotyphosa, L icterohaemorrhagiae, L pomona, or L Bratislava', and infectious tracheobronchitis ("kennel cough") caused by Bordetella bronchiseptica or rabies virus (RV).
[0178] In an embodiment, the dog is vaccinated against one or more of canine distemper caused by canine distemper virus(CDV); infectious canine hepatitis caused by canine adenovirus type 1 ; respiratory disease caused by canine adenovirus type 2 (CAV-2) or canine respiratory coronavirus; canine parainfluenza caused by canine parainfluenza virus; enteritis caused by canine coronavirus or canine parvovirus (CPV); leptospirosis caused by Leptospira canicola, L grippotyphosa, L icterohaemorrhagiae, L pomona, or L Bratislava', and infectious tracheobronchitis ("kennel cough") caused by Bordetella bronchiseptica or rabies virus (RV).
[0179] In another embodiment, the dog is vaccinated before receiving the atinvicitinib. In another embodiment, the dog is vaccinated simultaneous to receiving the atinvicitinib.
[0180] In another embodiment, the dog is vaccinated after receiving the atinvicitinib.
[0181] In another embodiment, the vaccine is one that protects the dog against canine distemper virus (CDV).
[0182] In another embodiment, the vaccine is one that protects the dog against canine adenovirus type 2 (CAV-2).
[0183] In another embodiment, the vaccine is one that protects the dog against canine parvovirus (CPV).
[0184] In another embodiment, the vaccine is one that protects the dog against rabies virus (RV).In another embodiment, the effective dose atinvicitinib is between about 0.1 to about 6.0 mg / kg, between about 1.0 to about 4.0 mg / kg, between about 1.0 to about 2.0 mg / kg, or between about 2.0 to about 3.0 mg / kg.
[0185] In an embodiment one or more antibodies titers of the one or more vaccines are maintained at therapeutic levels.
[0186] In another embodiment, the one or more of the antibodies titers are measured at the following levels:
[0187] i) CDV (VN50 > 32)
[0188] ii) CPV (HAI > 80)
[0189] iii) CAV-2 (VN50 > 16) or
[0190] iv) RV > 0.5 lU / mL).
[0191] In another embodiment, the one or more of the antibodies titers are measured at about 20 days, 30 days, 45 days, 56, days, 60 days, 68 days, 75 days, 90 days, 120 days, 150 days, 168 days 180 days, 8 weeks, 12 weeks, 16 weeks or 24 weeks.
[0192] In one embodiment the adequate immune response to the concomitantly administered vaccine is tested at 8 weeks after vaccination.EXAMPLES
[0193] The following examples are intended to be illustrative and non-limiting and represent a few specific embodiments of the present invention. It is to be understood that the above examples and descriptions are intended to be illustrative and not restrictive. Many embodiments will be apparent to those of skill in the art upon reading the above description. The scope of the invention should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled. All of the methods disclosed and claimed herein can be executed without undue experimentation in light of the present disclosure. While the methods of this invention have been described in terms of various embodiments, it will be apparent to those of skill in the art that variations may be applied to methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit, and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
[0194] 24-week study involving 20 healthy, 6-month-old vaccination naive Beagle dogs, evaluated the serological response to vaccination during treatment with atinvicitinib tablets at three times the maximum recommended dose of 1.2 mg / kg. Twenty dogs were randomly assigned to receive either atinvicitinib (3.6 mg / kg) (group 1) or placebo (group 2) once daily for 12 weeks. Vaccinations included a combination vaccine (Nobivac Canine 3-DAPv: modified live canine distemper virus (CDV), canine adenovirus type 2 (CAV-2), canine parvovirus (CPV)) at weeks 4 and 8, and a single dose of inactivated rabies virus (RV) vaccine (Nobivac 3-Rabies)_at week 4. Serology (antibody titers) was assessed at week 12 and dogs were observed for a further 12 weeks.
[0195] The total in life phase of the study was 168 days.
[0196] General health observations were conducted daily until the end of the in-life phase (D168). Clinical observations were conducted daily from D-28 until the end of the in-life phase. Samples were collected for serology and clinical pathology (D-14, -1 , 28, 56, 84 and 168) and for bioanalysis on D-1 , 28, 56, 77 / 78 (12-hour period analysis) and 84.
[0197] All animals assigned to both groups were confirmed naive at the start of the study for Canine Adenovirus (CAV-2), Canine Distemper Virus (CDV), Canine Parvovirus (CPV) and Rabies Virus (RV). On Days 56, 84 and 168, all animals were found to have protective levels of antibodies against CDV (VN50 > 32), and CPV (HAI > 80). On Days 56, 84 and 168, all animals for which tests were completed were found to have protective levels of antibodies against CAV-2 (VN50 > 16). All animals were found to have protective levels of antibodies against Rabies Virus (> 0.5 lU / mL) on Days 56 and 84, and on 168.
[0198] The daily treatment of dogs with atinvicitinib at 3 times the maximum clinical dose for a period of12 weeks was well tolerated in all dogs and had no negative effects on the immune response to Nobivac Canine 3-DAPv (CDV, CAV-2, CPV) and Nobivac 3-Rabies vaccination. All treated dogs achieved titer levels above those required for protective immunity for each vaccine antigen on D84.
[0199] Blood sample collection was taken approximately 4 hr (+ / - 5min) after dosing. Blood was sampled from the jugular or cephalic vein. Combined blood samples were taken at the following time points for analysis:
[0200] D -14: Serology and clinical pathology (incl. urine) (total blood volume sampled ~6ml)
[0201] D -1: Serology, clinical pathology (incl. urine) and bioanalysis (total blood volume sampled ~8ml)
[0202] D 28: Serology, clinical pathology (incl. urine) and bioanalysis (total blood volume sampled ~8ml)
[0203] D 56: Serology, clinical pathology (incl. urine) and bioanalysis (total blood volume sampled ~8ml)
[0204] D 84: Serology, clinical pathology (incl. urine) and bioanalysis (total blood volume sampled ~8ml)D 168: Clinical pathology (incl. urine) (total blood volume sampled ~4ml) The serum blood samples for serology were analysed as follows:
[0205] Canine Parvovirus (CPV) Haemagglutination Inhibition Assay
[0206] Antibodies to CPV were determined by haemagglutination inhibition assay (HAI). The HAI assay measures the ability of serum CPV antibodies to inhibit the agglutination of pig red blood cells. In short, diluted heat inactivated serum samples are adsorbed against porcine red blood cells to block any non-specific haemagglutination (overnight at 2-8°C or approx. 1h at approx. 37°C). The serum dilutions were then incubated with approximately 8 HA units of CPV on a 96 well plate at 37°C for 1 hour to 1 hour 10 minutes. The plates were incubated at 2-8°C for 15 to 20 minutes, 1% porcine red blood cells were added and the plates incubated at 2-8°C for 1.5 to 2.5 hours. The inhibition of haemagglutination was characterized by tear-dropping of the pig blood cells. The HAI titre of the sample is the reciprocal of the last dilution at which inhibition of agglutination occurs (<50% agglutination). Each serum sample was tested at two different pre-dilutions and the average against 4 HA units was reported. However, in the case of serum samples with antibody titres that are below (<) the limit of detection, only the HAI result from the lowest pre-dilution were given. In case of serum samples with antibody titres whose endpoint is above (>) the limit of detection, only the HAI result from the highest dilution was given.
[0207] Canine Distemper Virus (CDV) Virus Neutralisation Assay
[0208] Antibodies to CDV were determined in a virus neutralisation (VN) assay. The VN assay measures the ability of serum CDV antibodies to neutralize the infection of cells in culture. Briefly, CDV antibody titres were detected by making serial serum dilutions and incubating them with an equal volume of a known titre suspension of CDV. The dilutions were inoculated into wells of a micro titration plate containing Vero cells and incubated for 5-7 days. The virus neutralising antibody titre was calculated as the reciprocal of the highest dilution of the serum that shows complete neutralization of the virus (absence of CPE). The serum VN50 titre was calculated using the method of Reed & Muench [1], Reed & Muench is a validated calculation program in the CBA software system. See Reed, L.J. and Muench, H. (1938) ASimple Method of Estimating 50% Endpoints. American Journal of Hygiene, 27, 493-497.
[0209] Canine Adenovirus (CAV) Virus Neutralisation Assay
[0210] Antibodies to CAV were determined in a virus neutralisation (VN) assay. The VN assay measures the ability of serum CAV antibodies to neutralize the infection of cells in culture. Briefly, CAV neutralising antibody titres were detected by making serial serum dilutions and incubating them with an equal volume of a known titre suspension of CAV. After incubation, the samples were inoculated into wells of a micro titration plate containing MDCK cells and incubated for 6 days. The presence of virus within the tissue culture media was measured in a haemagglutination assay (HA) using Human type 0 red blood cells. The wells were scored positive or negative for agglutination. The VN50 titre of the serum, based on HA, is calculated by Reed & Muench. Reed & Muench is a validated calculation program in the CBA software system. The VN50 titre of neutralising antibodies against CAV in serum is the reciprocal of the dilution calculated to be the 50% end point.
[0211] Rabies Virus (RV) Rapid Fluorescent Focus Inhibition Test
[0212] Antibodies to Rabies will be determined by a Rapid Fluorescent Focus Inhibition Test (RFFIT). The RFFIT test measures the ability of serum Rabies antibodies to neutralize the infection of cells in culture. Briefly, 3-fold serial dilutions of the sera to be examined were made and mixed with an equal volume of a known titre suspension of Rabies virus. The sera / virus mixture is incubated at 37°C + 5% CO2. To grow non-neutralized virus after a pre-incubation period, susceptible cells were added into the mixture and incubated to form a monolayer. After incubation and rabies virus specific immunostaining, the monolayers were observed for fluorescent foci by microscopy. The lll / ml titre of neutralising antibodies against Rabies in serum is the interpolation of the dilution calculated to be the 50% inhibition point and referenced to the second WHO standard.
[0213] Atinvicitinib was extracted from plasma by protein precipitation. Reversed-phase liquid chromatography coupled with tandem mass spectrometry was used to quantify atinvicitinib.All dogs in both groups developed antibody titers that meet established thresholds for clinical protection against CDV (VNso>32), CAV-2 (VNso>16), CPV (HAI >80) and RV (>0.5 lU / mL). See World Small Animal Veterinary Association (WSAVA) Vaccination Guidelines, Journal of Small Animal Practice, 2024.
[0214] There was no impact on immune response to vaccination. The veterinary medicinal product containing atinvicitinib was well-tolerated with no adverse clinical effects and no signs of immune suppression or secondary infections (euthanasia, papillomas, pneumonia, severe illness due to Potential reactivation of vaccine virus) related to treatment when used concomitantly with vaccination. An adequate immune response (serology) to modified live Canine Adenovirus type-2 (CAV), modified live Canine Distemper Virus (CDV), modified live Canine Parvovirus (CPV), and inactivated Rabies Virus (RV) vaccination was achieved in study animals when 6-month-old vaccine naive puppies were administered the veterinary medicinal product at
[0215] 3.6 mg / kg atinvicitinib (3X the maximum labelled dose) once daily for 84 days.
Claims
CLAIMS1. A veterinary pharmaceutical composition comprising an effective dose of atinvicitinib and a pharmaceutically acceptable carrier for use in the treatment of a dog against allergic dermatitis including atopic dermatitis without the need to withdraw treatment prior or post vaccination, characterized in that the composition is administered concomitantly with vaccination and results in adequate immune response to vaccination.
2. The composition for use according to claim 1 , characterized in that the adequate immune response is at about 8 weeks or about 12 weeks or about 16 weeks after vaccination.
3. The composition for use according to any one of claims 1 to 2, characterized in that the vaccine includes live, attenuated strains of pathogens.
4. The composition for use according to any one of claims 1 to 3, characterized in that the concomitantly administered vaccine comprises one or more of the antigens that protect dogs against canine distemper caused by canine distemper virus; infectious canine hepatitis caused by canine adenovirus type 1 ; respiratory disease caused by canine adenovirus type 2 or canine respiratory coronavirus; canine parainfluenza caused by canine parainfluenza virus; enteritis caused by canine coronavirus or canine parvovirus; leptospirosis caused by Leptospira canicola, L grippotyphosa, L icterohaemorrhagiae, L pomona, or L Bratislava', and infectious tracheobronchitis ("kennel cough") caused by Bordetella bronchiseptica.
5. The composition for use according to any one of claims 1 to 4, characterized in that the vaccine comprises antigens that protects dogs against a disease caused by a pathogen selected from the group consisting of canine distemper virus (CDV), canine adenovirus type 2 (CAV-2), canine parvovirus (CPV)) and / rabies virus (RV).
6. The composition for use according to any one of claims 1 to 5, characterized in that the concomitantly administered vaccine comprises modified live Canine Adenovirus type-2 (CAV), modified live Canine Distemper Virus (CDV), modified live Canine Parvovirus (CPV), and / or inactivated Rabies Virus (RV).
7. The composition for use according to any one of claims 1 to 6, characterized in that the adequate immune response is an adequate serological immune response.
8. The composition for use according to any one of claims 1 to 7, characterized in that the adequate serological immune response is one or more ofi) CDV having (VN50 level of at least > 32)ii) CPV (HAI > 80)iii) CAV-2 (VN50 > 16) oriv) RV (> 0.5 lU / mL).
9. The composition for use according to any one of claims 1 to 8, characterized in that the effective dose of atinvicitinib is between about 0.1 to about 6 mg / kg.
10. The composition for use according to any one of claims 1 to 9, characterized in that the atinvicitinib is administered once daily at a daily dose of 0.5-3.6 mg / kg BW.
11. The composition for use according to any one of claims 1 to 10, characterized in that the daily dose is 0.8-1.2 mg / kg bodyweight of the animal.
12. The composition for use according to any one of claims 1 to 11 , characterized in that the composition is administered concomitantly with vaccination at the same time or within 28 days of each other, and wherein the immune response to the vaccine composition is non-inferior compared to a mono-administration of the vaccine composition without concomitant administration of the atinvicitinib composition.
13. The composition for use according to any one of claims 1 to 12, characterized in that the treated dog is vaccine naive.
14. The composition for use according to any one of claims 1 to 13 characterized in that the dog is younger than 12 months.
15. The composition for use according to any one of claims 1 to 14 characterized in that the dog is at least 6 months old.
